Clinical Trial

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-04; most recent amendment 2023-10-11.
Trial Details
NCT Number NCT05988697
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions NSCLC, BRAF V600E Mutation, Advanced Cancer, Stage IIIB NSCLC, Stage IV NSCLC
Enrollment 36 participants
Start Date 2023-11-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-04-01 (estimated)
Updated on ClinicalTrials.gov 2023-10-12